Thyrocare Technologies

Thyrocare Technologies board had fixed November 28 as the record date for its 2:1 bonus share issue. This smallcap stock has gained 40 per cent in the last two months.

Thyrocare Technologies share price surged following a strong September quarter (Q2FY26) financial performance.

Thyrocare Technologies shares zoomed 12.66 per cent in trade, hitting a 52-week high at ₹1,356.95 per share on the BSE.

Share price of Thyrocare Technologies has moved higher by 11 per cent to ₹938.65 on the BSE in Friday's intra-day trade and recovered 13 per cent from its intra-day low of ₹830.90.

Thyrocare Technologies share price: In Q4, the company's consolidated net profit including exceptional items stood at ₹21.3 crore as compared to ₹17.2 crore a year ago

Q4 FY25 company results today: Bajaj Housing Finance, Thyrocare Technologies, and Tata Teleservices will be among 28 companies to post earnings reports for the January-March quarter

Thyrocare on Thursday announced its financial results for the quarter and nine months ended December 31, 2024

5 stock ideas for Samvat 2081: ICICI Bank, ITC, Macrotech Developers, Varun Beverages and Thyrocare Technologies can rally up to 54%, suggests technical charts.

Thyrocare Technologies stock surged up to 16.75 per cent at Rs 759 per share on the BSE in Wednesday's intraday trade

Buzzing stocks to watch today, July 3: Avenue Supermarts, the DMart chain of stores' operator reported a provisional standalone revenue of Rs 13,712 crore for the June quarter, up 18 per cent Y-o-Y

Shares of Thyrocare Technologies hit a 21-month high of Rs 722 as they rallied 12 per cent on the BSE in Wednesday's intraday trade amid heavy volumes

Thyrocare is diagnostic chains that conduct an array of medical diagnostic tests and profiles of tests that centre on early detection and management of health disorders and diseases.

Reports suggest that Union Health Minister Mansukh Mandaviya will review the Covid-19 pandemic situation, in view of a spurt in COVID-19 cases in Japan, South Korea, Brazil, China and the US.

According to the technical analyst from Anand Rathi, Metropolis Healthcare can rally to Rs 1,800, while Thyrocare Technologies can rise up to Rs 740.

An entity on Monday offloaded 5.88 lakh shares of diagnostic chain Thyrocare Technologies Ltd for Rs 36 crore through an open market transaction. Fundsmith Emerging Equities Trust Plc sold 3,20,000 shares on BSE and 2,68,707 shares on NSE, amounting to a 1.1 per cent stake in the company, as per the bulk deal data available with the National Stock Exchange and BSE. The shares were disposed of at an average price of Rs 615.14 apiece on BSE and Rs 614.79 on NSE, taking the combined transaction value to Rs 36.20 crore. However, buyer(s) of the shares could not be ascertained. As of June quarter, Fundsmith held 1.15 per cent stake in the company, shareholding pattern showed with the exchange. Shares of Thyrocare Technologies closed 2.97 per cent lower at Rs 610 apiece on BSE and slipped 2.65 per cent on NSE.

Thyrocare, Dr Lal Path Labs and Metropolis are trading almost 50 per cent below their respective all-time highs, the reversal may see breakout if the key respective levels are sustained

A graduate of IIM-B, Guha has spent almost 17 years at Boston Consulting Group (BCG), where he has led the healthcare and life sciences practice

Given the weakness seen on Monday, should you be worried regarding stocks from this sector? Here is how they look on the charts

Docon Technologies, along with API Holdings, the parent company of unicorn PharmEasy, also made an open offer for acquisition of additional 26% stake in Thyrocare at a price of Rs 1,300 per share

The combined entity will have the ability to provide diagnostics and pharmacy services to 100 million-plus Indians within 24 hours, the company said in a statement